Knowledge, Attitudes, and Practices of Libyan Healthcare Providers Regarding GLP-1 RA FDA Safety Warnings

Background: Following crucial FDA safety warnings about intestinal obstruction (2023) and suicidal thoughts (2024) related with GLP-1 receptor agonists (GLP-1 RAs), this study evaluated Libyan healthcare providers' (HCPs) knowledge, attitudes, and practices (KAP) in light of these updates. Methods: A validated questionnaire was used to perform a cross-sectional research of 232 Libyan HCPs prescribing GLP-1 RAs (Pharmacists and Physicians). Data were collected by in-person administration. The study was conducted using descriptive statistics, chi-square tests, ANOVA, and logistic regression. Results: Pharmacists, who were the principal prescribers (62.5%), mostly in community settings (44.2%), displayed understanding of FDA warnings (e.g., 55.3% correctly identified the ileus/suicide combination). However, major knowledge-practice gaps were found: 71.5% of pharmacists advised against fiber intake for ileus treatment, and 68.6% mistakenly characterized type 1 diabetes as an absolute contraindication. Pharmacists reported the greatest impact of warnings on prescription (72.0% strongly agreed), but poor trust in handling side effects (mean=3.28, p=0.002). Low screening adherence was found (10.7% "always" tested). "Lack of time" (58.6%) and "patient demand" (65.5%) were two of the challenges identified. Pharmacists favored FDA quick-reference guides (75.0%). Conclusion: Libyan pharmacists are the main GLP-1 RA prescribers, but critical knowledge-practice disconnects and low confidence exist despite awareness of FDA warnings. Identified barriers necessitate tailored interventions and practical workflow tools to mitigate patient safety risks.